AU Patent

AU2024232125A1 — Compounds of drugs with an albumin binding moiety

Assigned to Ascendis Pharma AS · Expires 2025-08-28 · 1y expired

What this patent protects

The present application relates to compounds or pharmaceutically acceptable salts thereof, wherein the compounds comprise at least one polymeric moiety, to which at least two drug moieties are covalently and reversibly conjugated, which drug moieties are conjugated to an albumin …

USPTO Abstract

The present application relates to compounds or pharmaceutically acceptable salts thereof, wherein the compounds comprise at least one polymeric moiety, to which at least two drug moieties are covalently and reversibly conjugated, which drug moieties are conjugated to an albumin binding moiety. The application also relates to pharmaceutical compositions comprising at least one such compound and their medical uses.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024232125A1
Jurisdiction
AU
Classification
—
Expires
2025-08-28
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.